XVIVO Perfusion
XVIVO.ST Mid CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
XVIVO Perfusion en bref
XVIVO Perfusion (XVIVO.ST) is currently trading at 263,80 € with a market capitalization of 7,2 Md €. The trailing P/E ratio stands at 93.55x, with a forward P/E of 44.64x. The 52-week range spans from 160,00 € to 310,40 €; the current price is 15% below the yearly high. Year-over-year revenue growth stands at +34.0%. The net profit margin stands at 9.89%.
💰 Dividende
XVIVO Perfusion currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
5 analystes évaluent XVIVO Perfusion (XVIVO.ST) au consensus : Achat Fort. L'objectif de cours moyen est de 335,60 €, soit un potentiel de +27.22% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 300,00 € à 385,00 €.
XVIVO Perfusion : la thèse d'investissement en détail
XVIVO Perfusion (XVIVO.ST) operates in the Healthcare — specifically Medical Devices — and is headquartered in Sweden. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 34% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 72.27%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 27.22% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 51.35x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 44.64x is meaningfully below the trailing 93.55x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 27.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 34% sur un an
- Marge brute élevée de 72.27% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 5.53)
- –Multiple de valorisation élevé (P/E 93.55x)
- –Actuellement jugée surévaluée
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy XVIVO Perfusion?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news